RSS Feeds
Hepatic Histologic and Immunohistochemical Changes in Chronic Hepatitis B after Prolonged Clearance of Hepatitis B e Antigen and Hepatitis B Surface Antigen
- Robert P. Perrillo, MD; and
- Elizabeth M. Brunt, MD
Excerpt
The treatment of chronic hepatitis B with recombinant alpha-interferon results in the disappearance of hepatitis B e antigen (HBeAg) and hepatitis B virus DNA (HBV DNA) from serum in nearly 40% of patients (1, 2). In addition, hepatitis B surface antigen (HBsAg) seroconversion occurs in approximately one third of responders (2). Improvement in serum aminotransferase levels and partial resolution of hepatic inflammation have been seen in most responders when evaluated 6 to 12 months after the completion of therapy (2-4). Whereas recent data indicate that the disappearance of serum markers for viral replication and improvement in liver function are often
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
Acknowledgment: The authors thank Carol J. Bodicky, RN, for her assistance in the performance of the study.
Article and Author Information
-
From St. Louis Veterans Affairs Medical Center and Washington University School of Medicine, St. Louis, Missouri. For current author addresses, see end of text.
-
Requests for Reprints: Robert P. Perrillo, MD, Veterans Affairs Medical Center (111 JC), 915 North Grand Boulevard, St. Louis, MO 63106.
-
Current Author Addresses: Dr. Perrillo: Veterans Affairs Medical Center (111 JC), 915 North Grand Boulevard, St. Louis, MO 63106.
Dr. Brunt: Barnes Hospital, Surgical Pathology, 3d Floor, Old Children's Hospital, Room 120, One Barnes Hospital Plaza, St. Louis, MO 63110.
